Morgan Stanley Lowers Rating on Humana, Flags Medicare Advantage and 2026 Bid Risks
Morgan Stanley cut Humana's rating to Underweight from Equal-weight and trimmed its price target to $174 from $262, citing policy-driven reimbursement risks and concerns about the insurer's 2026 Medicare Advantage bidding strategy. The firm warned that flat benchmark rates in the Medicare Advantage Advance Rate Notice and Humana's expansion of pres…